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Abstract
Pre-clinical studies provide compelling evidence that Eph family receptor tyrosine kinases (RTKs) and ligands promote
cancer growth, neovascularization, invasion, and metastasis. Tumor suppressive roles have also been reported for the
receptors, however, creating a potential barrier for clinical application. Determining how these observations relate to clinical
outcome is a crucial step for translating the biological and mechanistic data into new molecularly targeted therapies. We
investigated eph and ephrin expression in human breast cancer relative to endpoints of overall and/or recurrence-free
survival in large microarray datasets. We also investigated protein expression in commercial human breast tissue
microarrays (TMA) and Stage I prognostic TMAs linked to recurrence outcome data. We found significant correlations
between ephA2, ephA4, ephA7, ephB4, and ephB6 and overall and/or recurrence-free survival in large microarray datasets.
Protein expression in TMAs supported these trends. While observed no correlation between ephrin ligand expression and
clinical outcome in microarray datasets, ephrin-A1 and EphA2 protein co-expression was significantly associated with
recurrence in Stage I prognostic breast cancer TMAs. Our data suggest that several Eph family members are clinically
relevant and tractable targets for intervention in human breast cancer. Moreover, profiling Eph receptor expression patterns
in the context of relevant ligands and in the context of stage may be valuable in terms of diagnostics and treatment.
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Introduction
According to the American Cancer Society, 207,090 new cases
of invasive breast cancer were anticipated for women in the U.S.
during 2010. Breast cancer is the second most frequently
diagnosed cancer in U.S. women, predicted to result in 39,840
deaths in 2010, and ranks second as a cause of cancer death in
women (ACS, Breast Cancer Facts and Figures 2010 Atlanta, GA).
Understanding the molecular mechanisms that regulate progres-
sion of this devastating disease is crucial for identifying novel
therapeutic targets. Current treatment options, such as adjuvant
chemotherapy or radiation, have improved survival, particularly in
women diagnosed with early stage breast cancer (ACS, Breast
Cancer Facts and Figures 2010 Atlanta, GA). Existing treatments,
however, are often accompanied by undesirable side effects that
significantly reduce patient quality of life (e.g. gastrointestinal
discomfort, lymphedema, menopausal-like symptoms/premature
menopause, impaired cognitive function/neurotoxicity, adverse
physical and psychological effects on sexuality) and/or increase the
risk of mortality [e.g. cardiac toxicity, increased risk for secondary
cancers, bone loss; reviewed in [1,2,3,4]]. One of the proposed
benefits for new, molecularly targeted therapies is the potential to
reduce morbidity associated with cancer as well as mortality.
Several pre-clinical and laboratory studies support the function
of Eph receptor tyrosine kinases (RTKs) in tumor growth,
metastasis, and neovascularization [reviewed in [5,6,7]], including
breast cancer [reviewed in [8]]. The Eph family of RTKs is the
largest identified in the vertebrate genome and is subdivided into
class A and class B based on sequence homology and binding
affinity for two distinct types of membrane-anchored ephrin
ligands. Class A receptors normally interact with glycosyl-
phosphatidylinositol (GPI)-linked class A ephrins, while class B
receptors generally bind to class B ephrins that are attached to the
cell membrane by a transmembrane-spanning domain, although
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24426interclass binding does occur among certain family members [5].
Originally characterized as axon guidance regulators, ephrins and
Eph RTKs regulate physiologic and pathologic processes during
embryonic development, in normal tissue homeostasis, and in
disease [reviewed in [5,6,9]], making them attractive candidates
for new molecularly targeted therapies, particularly in cancer.
However, with 14 receptors (9 class A and 5 class B) and 8 ligands
(5 class A and 3 class B) present in the human genome, expression
patterns that often overlap, and promiscuous interaction between
ligands and receptors that include bi-directional signaling and
pleiotropic functions, the role of Eph receptors in cancer is
extremely complex [5]. Moreover, the role of Eph and ephrin
molecules in tumor progression remains controversial, with
evidence suggesting both tumor promoting and tumor suppressive
functions [reviewed in [5,8]].
We sought to address this controversy by profiling expression of
Eph RTKs and ephrin ligands in human breast cancer. We
compared mRNA expression levels with clinical outcome in
human breast cancer microarray datasets, as well as protein
expression in tumor epithelium in human breast cancer tissue
microarrays. These analyses confirmed the relevance of EphA2
and EphB4 to human breast cancer progression, and uncovered
significant correlations for EphA4, EphA7, and EphB6, which
were previously under-investigated in breast cancer. Coupled with
human breast cancer TMAs for which clinical data were available,
our data suggest that several Eph family members are clinically
relevant and tractable targets for intervention in human breast
cancer. Our data further suggest that profiling Eph RTK
expression in the context of ligand expression and stage may
prove more informative in terms of diagnostics and patient
selection for molecularly targeted therapy trials using anti-Eph
RTK agents.
Results
Elevated RNA expression of many Eph RTKs significantly
correlates with poor outcome in human breast cancer
Several reports in the literature provide evidence that individual
Eph receptors contribute to breast tumorigenesis and progression
[reviewed in [8]]. The clinical relevance of these observations,
however, remains under-investigated. Moreover, expression pat-
terns for several members of this large RTK family have yet to be
determined in cancer. To address these gaps in our knowledge, we
profiled the expression of individual Eph and ephrin family
members in relation to overall and/or recurrence free survival in
two independent breast cancer patient datasets [10,11]. In the van
de Vijver dataset, consisting of 295 patient samples, relatively high
RNA expression levels of ephA2, ephA4, ephA7, ephB4, and ephB6
correlated significantly with reduced overall survival (Figures 1&2).
Similar trends were observed for recurrence-free survival in this
dataset (Figure S1&2), as well as metastasis-free survival in the
independent van’t Veer dataset that consisted of 117 patient
samples (Figures S3&S4). We did not observe any positive or
negative associations between expression level and clinical
outcome for other Eph RTK family members analyzed, nor did
we observe any significant associations between any ephrin ligand
family member expression and outcome (data not shown; note that
ephA6 and ephrin-A2 probes were not represented in these datasets).
Analysis of estrogen and progesterone receptor RNA expression
and clinical outcome were used as internal controls (Figure S5).
The Kaplan-Mier curves were generated using relative
expression data from the top and bottom quartiles of high and
low expression. When we analyzed ephA2, ephA4, ephA7, ephB4, and
ephB6 as continuous covariates using the entire dataset, Cox model
analysis supported the observed association between these receptor
family members and overall survival in the van de Vijver dataset
(Table 1) and metastasis-free survival in the Veer dataset (Table
S1), with EphA2 expression showing the most consistent,
significant association with poor outcome. Our analyses suggest
that these specific Eph RTK family members are the most
clinically relevant to breast cancer, making them attractive
candidates for further analysis.
Eph RTKs associated with poor clinical outcome are also
overexpressed at the protein level in human breast
cancer samples
We evaluated protein expression of EphA2, EphA4, EphA7,
EphB4, and EphB6 in human breast cancer tissue microarrays
(TMA) in which we could distinguish expression in tumor
epithelium from stromal components, including endothelium.
We compared expression in normal and hyperplastic breast tissue
to levels observed in invasive ductal carcinoma using a continuous
scale to rank relative expression in tumor epithelium based on the
percentage of positive tumor epithelial cells within each core as
well as relative intensity of staining. A significantly higher
percentage of human invasive ductal carcinoma samples displayed
expression of EphA2, EphA4, or EphA7 in tumor epithelium
relative to ‘normal’ samples (normal/hyperplastic or fibroadeno-
ma), which were largely negative (Figure 3). EphB4 and EphB6
were also significantly elevated in tumor epithelium relative to
‘normal’ samples (Figure 4). By contrast, EphA8, which was not
significantly associated with clinical outcome in the microarray
datasets, did not show significant elevation in human breast cancer
tissue relative to controls (Figure S6). Antibody specificity was
validated using tissue from targeted deletion mutant mice or
peptide competition (Figure S7). Together, these data suggest that
RNA expression profiles within the microarray datasets correlate
with protein expression levels in tumor epithelium.
Ephrin-A1 association with EphA2 and clinical outcome
Although we did not observe any significant associations
between ephrin ligand expression and clinical outcome, several
studies suggest that ephrins do play a role in breast tumor
progression and angiogenesis [reviewed in [12]]. Ligand-depen-
dent versus ligand-independent signaling has emerged as one key
mechanism underlying the tumor suppressive functions as opposed
to oncogenic effects of Eph RTKs. Thus, we analyzed co-
expression of ephrin-A1, the primary ligand for EphA2, and
EphA2 protein in a large Stage I prognostic TMA from the NCI
Cooperative Breast Cancer Tissue Resource (CBCTR) Cancer
Diagnosis Program (CDP). This TMA consists of over 500 breast
cancer plus normal breast tissue samples that are linked to
recurrence outcome data (http://cdp.nci.nih.gov/breast/prognostic_
tma.html).
We stained duplicate slides with anti-ephrin-A1 or anti-EphA2
antibodies that were validated using mammary tissue from genetic
deletion mouse models (Figure S7) and quantified the percent
positive tumor epithelium and relative staining intensity using a
computer-based Ariol platform. Expression of EphA2 was not
statistically associated with recurrence, nor was there a correlation
between ephrin-A1 and recurrence (data not shown). Pearson’s
product-moment correlation, however, revealed a statistically
significant correlation (r=0.4982) between ephrin-A1 and EphA2
coexpression when analyzed as continuous variables in the subset
of 72 patients that displayed disease recurrence [p-value ,0.0001;
95% CI=0.2998, 0.6554].
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the non-recurrent patients was completed using the bootstrap
based correlation analysis. We randomly selected (with replace-
ment) a sample size of 72 from 446 non-recurrent patients 10,000
times. The mean correlation between ephrin-A1 and EphA2 from
the bootstrap analysis was 0.3475 (p-value .0,05), which was not
statistically significant.
These data were consistent with our observations in commercial
TMAs in which EphA2 and ephrin-A1 proteins were co-expressed
in ductal carcinoma samples confined to the breast (Figure 5). In
infiltrating ductal carcinoma samples that metastasized to lymph
node, however, we observed that a significant portion of the
samples displayed mutually exclusive staining patterns for EphA2
and ephrin-A1 (p,0.05, Chi square analysis; n=32 total lymph
Figure 1. RNA expression of EphA2, EphA4, and EphA7 negatively correlates with overall survival in human breast cancer. Kaplan-
Meier kinetic analyses of the van der Vijver dataset, with microarray profiles of 295 human breast tumors and associated clinical data. The impact of
elevated ephA2 (A), ephA4 (B), and ephA7 (C), expression on overall survival was analyzed by Log-Rank tests.
doi:10.1371/journal.pone.0024426.g001
Eph/Ephrin Expression Breast Cancer Outcome
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A1+/EphA22 and 8 ephrin-A12/EphA2+). In the subset of
samples that were ephrin-A1+ (11 out of 32), 2 were ephrin-A1+/
EphA2+ and 9 were ephrin-A1+/EphA22 (p,0.05, Chi square
analysis). Together, these data suggest that while co-expression of
receptor and ligand in early stage breast cancer may contribute to
recurrence, loss of ephrin-A1 ligand in metastatic samples may
contribute to invasion, as suggested by laboratory studies
[reviewed in [5,12]].
Discussion
Studies using both murine and human cancer cell lines in
culture and in allograft/xenograft models, as well transgenic and
gene-deletion mouse models, provide strong evidence that several
members of the Eph family of receptor tyrosine kinases and their
ephrin ligands regulate tumorigenesis and progression [reviewed in
[5]]. Although some previous studies included expression analysis
in patient samples, large-scale expression profiling for these
molecule in relation to clinical outcome has been limited,
including profiling in breast cancer. In this study, we analyzed
large microarray datasets for human breast cancer samples linked
to clinical data, as well as human breast tissue microarrays, to
identify associations between specific Eph and ephrin family
members and overall survival and/or recurrence. We observed a
significant negative association between expression of EphA2 and
EphB4 and outcome, consistent with previous preclinical studies.
In addition, we uncovered previously uncharacterized associations
between expression of EphA4, EphA7, and EphB6 and survival/
recurrence, highlighting the value of this strategy in uncovering
novel, clinically relevant targets. Although we did not observe any
significant associations with ephrin ligand expression and clinical
outcome, co-expression of EphA2 and ephrin-A1 in Stage I breast
cancers correlated with recurrence. By contrast, a disproportionate
number of metastatic ductal carcinoma samples that were EphA2
positive displayed little or no ephrin-A1 expression. These data
suggest that profiling Eph receptor expression patterns in the
context of relevant ligands may be valuable in terms of diagnostics.
Of the A class Eph RTKs, EphA2 is most extensively studied in
breast cancer [Reviewed in [5,8]]. Our profiling data are
consistent with previous studies reporting that EphA2 is expressed
at low levels in normal breast epithelium [13,14] and overex-
pressed in 60–80% of breast cancers [15,16,17]. Forced
overexpression of EphA2 resulted in malignant transformation of
non-transformed MCF10A breast cells [16], whereas Conversely,
siRNA-mediated inhibition of EphA2 or overexpression of
dominant-negative EphA2 constructs suppressed growth and
metastasis of MMTV-Neu tumor cells and 4T1 metastatic mouse
mammary adenocarcinoma cells, respectively, in vivo [18,19].
Figure 2. RNA expression of EphB4 and EphB6 negatively correlates with overall survival in human breast cancer. Kaplan-Meier
kinetic analyses of the van der Vijver dataset, with microarray profiles of 295 human breast tumors and associated clinical data. The impact of
elevated ephB4 (A) and ephB6 (B) expression on overall survival was analyzed by Log-Rank tests.
doi:10.1371/journal.pone.0024426.g002
Table 1. Association between Eph receptor expression and
overall survival in human breast cancer.
Eph Receptor RR Overall Survival (95% CI) P-Value
EphA2 8.52 (2.8–25.9) 0.0002*
EphA4 3.32 (1.49–7.39) 0.0003*
EphA7 3.55 (1.12–11.3) 0.0316*
EphB4 17.2 (1.91–155.1) 0.0111*
Cox Model Analysis: Relative risk (RR) associated with elevated Eph receptor
molecule expression and overall survival in the van de Vijver dataset.
*Statistically significant association.
doi:10.1371/journal.pone.0024426.t001
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controls. Immunohistochemical analysis of human breast tissue microarrays (TMAs) was performed to compare relative expression in normal/benign
epithelium (n=8 samples) versus invasive ductal carcinoma (n=126 samples) for EphA2 (A), EphA4 (B), and EphA7 (C). Arrows indicate tumor
epithelium in photomicrographs. Scale bar=50 mm. *Differential expression between normal/benign and malignant epithelium was assessed using
Chi Square analysis.
doi:10.1371/journal.pone.0024426.g003
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epithelial growth and branching morphogenesis [12], as well as
tumor initiation and lung metastasis in the MMTV-Neu
transgenic model of mammary adenocarcinoma [18]. More
recently, EphA2 was reported to mediate resistance to trastuzu-
mab therapy [20], and to affect estrogen dependence and
tamoxifen sensitivity [21], in cell line and xenograft models.
Similarly, EphB4 levels are also elevated in human breast
cancer [22]. EphB4 knockdown inhibited breast cancer survival,
migration, and invasion in vitro and tumor growth in a xenograft
model in vivo [23]. Furthermore, overexpression of EphB4 in the
mammary epithelium accelerated tumor onset and lung metastasis
in MMTV-Neu animals [24]. Independent studies reported
EphB4 and EphB2 overexpression in human breast cancer
[22,25]. Higher EphB2 expression was associated with poor
overall and disease-free survival whereas EphB4 protein expres-
sion increased with grade and stage but showed no clear
association with survival. However, stronger EphB2 and EphB4
staining was reported in normal breast glandular epithelium than
in tumor epithelium [22,26], and systemic delivery of ephrin-B2-
Fc inhibited the growth of MDA-MB-435 tumor xenografts via
EphB4 mediated activation of the Abl/Crk pathway, which
inhibits tumor cell growth and motility in breast cancer cells [27].
These observations highlight the often paradoxical findings
regarding Eph RTKs in tumor promotion versus tumor
suppression [28]. Our analyses of multiple large patient datasets
revealed a correlation between elevated ephB4 mRNA expression
and reduced overall and recurrence-free survival. Thus, further
analysis of EphB4 expression in both tumor parenchyma and the
surrounding stroma is necessary, with human patient samples
carefully stratified by stage and grade, as well as by molecular
subtype and treatment regimen. Particular attention should be
paid to expression profiles in tumor endothelium, given the role of
B class receptors like EphB4 in angiogenesis and tumor
neovascularization [28], as well as vessel maturation and vascular
integrity [29].
While we did not observe any significant associations between
EphA5 and clinical outcome, an independent profiling study
reported reduced ephA5 expression in human breast cancer
samples relative to normal human breast tissue, likely due to
aberrant promoter methylation [30]. While several other studies
reported EphB6 promoter methylation and a tumor suppressor
function [31,32,33,34,35], our data revealed a significant associ-
ation between elevated ephB6 and poorer overall and recurrence-
free survival in breast cancer. The other negative associations that
we observed between survival/recurrence and elevated mRNA
expression of ephA2, ephA4, ephA7, and ephB4 are consistent with
laboratory data for some Eph family members (e.g. EphA2,
EphA7), but not others (e.g. EphA4, EphB4, EphB6), in human
breast cancer cell lines [31]. At least one explanation may be
ligand-independent versus dependent signaling. We found an
inverse correlation between EphA2 and ephrin-A1 protein
expression in a significant number of invasive ductal carcinoma
samples in lymph node relative to normal breast and ductal
carcinomas confined to the breast, which co-express both. This
observation is consistent with breast cancer cell line expression
Figure 4. Protein expression of EphB4 and EphB6 is elevated in human ductal carcinoma relative to normal/benign tissue controls.
Immunohistochemical analysis of human breast tissue microarrays (TMAs) was performed to compare relative expression in normal/benign
epithelium (n=8 samples) versus invasive ductal carcinoma (n=126 samples) for EphB4 (A) and EphB6 (B). Arrows indicate tumor epithelium in
photomicrographs. Scale bar=50 mm. *Differential expression between normal/benign and malignant epithelium was assessed using Chi Square
analysis.
doi:10.1371/journal.pone.0024426.g004
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inhibits tumor cell growth and invasion [36,37,38]. We also
observed, however, that co-expression of EphA2 and ephrin-A1
correlate with recurrence in Stage I prognostic TMAs. These data
hightlight the importance of profiling the full spectrum of relevant
ephrin-ligands as well as Eph RTKs in order to elucidate potential
differences in clinical outcome associated with the presence or
absence of ligand.
In summary, our analysis of expression profiles in large breast
cancer datasets and in breast cancer TMAs support the clinical
relevance for several Eph RTKs in human breast cancer. In
addition to confirming relevance of more well-studied family
members like EphA2 and EphB4, we also uncovered associations
between EphA4, EphA7, EphB2, and EphB6 and overall/
recurrence-free survival. The causal role of these Eph RTKs in
cancer, however, must be further investigated in cell lines and
animal models. Moreover, our data suggest the importance of
profiling Eph family members in the context of relevant ligands
and across a broad spectrum of stages in order to understand their
complex roles in human cancer.
Materials and Methods
Reagents
Antibodies against the following proteins were used: rabbit anti-
EphA2 (Life Technologies/Zymed Laboratories, Carlsbad, CA;
clone 347400); rabbit anti-EphA4 (Lifespan Biosciences, Seattle,
WA; clone LS-A2482; Abnova, Walnut, CA; PAB3007); rabbit
anti-EphA7 (Abgent, San Diego, CA; clone RB1641/RB1642)
and synthetic blocking peptide (Abgent; BP7612b); rabbit EphA8
(Abnova, PAB3015); rabbit anti-ephrin-A1 (Amgen/Immunex,
Thousand Oaks, CA; clone P2); rabbit anti-EphB4 (Abgent; clone
RB14731) and synthetic blocking peptide (Abgent; BP7625d);
rabbit anti-EphB6 (Abgent; clone AP7627b) and synthetic
blocking peptide (Abgent; BP7627b). Human breast tissue
microarrays (TMA) were purchased from Cybrdi, Inc. (Rockville,
MD), US Biomax (Rockville, MD), or from the National Cancer
Institute Cooperative Breast Cancer Tissue Resource (NCI
CBCTR). TMAs analyzed included breast carcinoma tissue array
panel I with normal breast tissue controls (Cybrdi, CC08-10-001)
and breast ductal carcinoma/metastasized to lymph nodes and
normal breast tissue array (Cybrdi, CC08-21-002), breast disease
spectrum tissue array/progression array (US Biomax, BR480), and
Stage I prognostic array (CBCTR). Biotin goat anti-rabbit IgG
was obtained from BD Biosciences (Pharmingen, San Diego, CA).
Streptvidin horseradish peroxidase conjugate was purchased Life
Technologies/Molecular Probes, and liquid 3,39-diaminobenzi-
dine tetrahydrochloride (DAB) substrate kit was from Life
Technologies/Zymed Laboratories. Meyer’s hematoxylin was
purchased from Sigma-Aldrich (St. Louis, MO).
mRNA expression profiling
Analysis of mRNA encoding human Eph RTK and ephrin gene
products in the human breast cancer datasets [10,11,39] was
performed in collaboration with the Vanderbilt-Ingram Cancer
Center’s Biostatistics Core Resource. Expression levels were
analyzed in relation to overall and/or recurrence-free survival
using Log Rank and Cox analyses.
Immunohistochemistry
Immunohistochemical staining for Eph RTKs and ephrin-A1
was performed as described previously [14]. Briefly, sections and
TMAs were deparaffinized with xylenes and rehydrated through a
series of graded alcohols to PBS. The sections were subjected to
thermal antigen retrieval in citrate buffer (2 mM citric acid,
10 mM sodium citrate, pH 6.0) using a PickCell Laboratories
2100 Retriever as per manufacturer’s instructions. Following a
brief wash in PBS, endogenous peroxidases were quenched by
incubation in 3% H2O2 solution (Sigma-Aldrich) for 30 minutes.
Figure 5. Inverse correlation between Ephrin-A1 and EphA2
expression in metastatic human breast cancer. Immunohisto-
chemical staining was performed for human breast cancer samples on
commercial TMAs. (A) We observed co-expression of EphA2 in several
infiltrating ductal carcinoma samples confined to breast tissue. (B) In
infiltrating ductal carcinomas that metastasized to the lymph node,
however, we observed that a significant portion of samples showed
mutually exclusive staining patterns for EphA2 and ephrin-A1 (p,0.05,
Chi Square analysis; n=32 total lymph node metastasis samples, 2 out
of 32 ephrin-A1+/EphA2+ versus 9 out of 32 ephrin-A1+/EphA22 and 8
out of 32 ephrin-A12/EphA2+). In the subset of samples that were
ephrin-A1+ (11 out of 32), 2 out of 11 were ephrin-A1+/EphA2+ versus 9
out of 11 ephrin-A1+/EphA22 (p,0.05, Chi Square analysis). Arrow-
heads indicate metastatic tumor cells embedded within lymph node
tissue. Scale bar=25 mm.
doi:10.1371/journal.pone.0024426.g005
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blocking solution from room temperature, and incubated
overnight at 4uC with primary antibodies diluted in blocking
solution. Sections were washed and incubated with biotinylated
secondary antibodies for 1 hour at room temperature. Sections
were incubated with diluted avidin-peroxidase reagent, washed,
and stained with DAB substrate. After hematoxylin counterstain,
sections were mounted and photographed on an Olympus BX60
microscope using a digital camera and NIH Scion Image software.
Where indicated, diluted antibodies were pre-incubated with
1 mg of competitor peptide for 1 hour at 4uC, rotating, prior to
incubation with tissue sections to control for specificity. Additional
controls included normal mouse kidney, liver, and small intestine.
For EphA2 and ephrin-A1, tissue from deficient mouse models
[18,40] was probed to confirm specificity of staining.
Scoring relative Eph and ephrin expression levels in TMAs
For commercial TMAs, relative expression was scored using a
continuous scale as follows: 0=0–10% positive tumor epithelium,
1=10–25% positive tumor epithelium, 2=25–50% positive
tumor epithelium, and 3=.50% positive tumor epithelium/core.
TMA cores were scored blind by three independent individuals,
the average of which was reported here. Differential expression
between tissue samples were quantified and statistically analyzed
using Chi square analysis.
For TMAs purchased from the NCI CBCTR, stained cores were
scanned and staining quantified using the Ariol SL-50 platform
through the Vanderbilt University Epithelial Biology Center (EBC).
Stainedcoreswerescanned andareasencompassingtumorepithelium
were selected for computer-based calculation of the percentage
positive tumor epithelium (DAB stained) relative to total tumor
epithelium (hematoxylin stained) with a scale for relative intensity.
Statistical Analyses
Statistical analyses were performed in collaboration with the
Vanderbilt-Ingram Cancer Center’s Biostatistics Core Resource
using Software: R2.12.1 [http://www.r-project.org/; [41]]. The
survival curves from Kaplan-Meier was created and plotted by the
function ‘‘survfit’’ under R package ‘‘survival.’’ P values shown on
KM plots were calculated based on log rank test between two
survival curves of high or low expression groups [42]. The c-
indexes shown on KM plots were calculated by the function
‘‘rcorr.cens’’ under R package ‘‘Hmisc’’ [43].
The association between individual gene expression level and
clinical endpoint (overall survival, metastasis-free survival, and
recurrence survival were analyzed with the use of a Cox
proportional hazard (PH) model. The function ‘‘coxph’’ in R
package ‘‘survival’’ was applied [44]. For analysis of ephrin-A1
and EphA2 protein expression in NCI CBCTR TMAs, we used
Pearson’s product moment correlation coefficient to test for
association between paired samples. The function ‘‘cor.test’’ in R
package ‘‘stats’’ was employed.
To rule out any potential over-fitting problem of the identified
correlation between EphA2 and ephrin-A1 co-expression and
recurrence in the Stage I prognostic TMAs, we used bootstrap
based correlation analysis. The ‘‘sample’’ method in R package
‘‘stat’’ is used perform the bootstrap analysis [45,46]. We
randomly selected (with replacement) a sample size of 72 from
446 non-recurrent patients 10,000 times.
Supporting Information
Figure S1 RNA expression of EphA2, EphA4, and EphA7
negatively correlates with recurrence-free survival in
human breast cancer. Kaplan-Meier kinetic analyses of the
van der Vijver dataset, with microarray profiles of 295 human
breast tumors and associated clinical data. The impact of elevated
ephA2 (A), ephA4 (B), and ephA7 (C), expression on recurrence-free
survival was analyzed by Log-Rank tests.
(TIF)
Figure S2 RNA expression of EphB4 and EphB6 nega-
tively correlates with recurrence-free survival in human
breast cancer. Kaplan-Meier kinetic analyses of the van der
Vijver dataset, with microarray profiles of 295 human breast
tumors and associated clinical data. The impact of elevated ephB4
(A) and ephB6 (B) expression on recurrence-free survival was
analyzed by Log-Rank tests.
(TIF)
Figure S3 RNA expression of EphA2, EphA4, and EphA7
negatively correlates with metastasis-free survival in
human breast cancer. Kaplan-Meier kinetic analyses of the
Veer, with microarray profiles of 117 human breast tumors and
associated clinical data. The impact of elevated ephA2 (A), ephA4
(B), and ephA7 (C), expression on metastasis-free survival was
analyzed by Log-Rank tests.
(TIF)
Figure S4 RNA expression of EphB4 and EphB6 nega-
tively correlates with metastasis-free survival in human
breast cancer. Kaplan-Meier kinetic analyses of the Veer
dataset, with microarray profiles of 117 human breast tumors and
associated clinical data. The impact of elevated ephB4 (A) and
ephB6 (B) expression on metastasis-free survival was analyzed by
Log-Rank tests.
(TIF)
Figure S5 RNA expression of ER and PR correlates with
overall and metastasis-free survival in human breast
cancer, validating microarray datasets. Kaplan-Meier
kinetic analyses of the van der Vijver and Veer datasets, with
microarray profiles of 295 and 117 human breast tumors and
associated clinical data, respectively. The impact of elevated
estrogen receptor ESR1 (A, C) and progesterone receptor PGR (B,
D) expression on overall and metastasis-free survival was analyzed
by Log-Rank tests.
(TIF)
Figure S6 RNA and protein expression of EphA8 in
human breast cancer. Kaplan-Meier kinetic analyses of the
van der Vijver (A) and Veer (B) datasets, with microarray profiles
of 295 and 117 human breast tumors and associated clinical data,
respectively. The impact of ephA8 expression on overall, recur-
rence-free, and metastasis-free survival was analyzed by Log-Rank
tests. (C) Immunohistochemical analysis of human breast tissue
microarrays (TMAs) was performed to compare relative expres-
sion in normal/benign epithelium (n=8 samples) versus invasive
ductal carcinoma (n=126 samples) for EphB4 (A) and EphB6 (B).
Arrows indicate tumor epithelium in photomicrographs. Scale
bar=50 mm. No statistically significant correlations between RNA
expression/clinical outcome or protein expression/malignancy
were observed.
(TIF)
Figure S7 Anti-Eph and ephrin antibody validation.
Immunohistochemical analysis of mouse mammary tissue from
wild-type (A, E), EphA2-deficient (A), or ephrin-A1-deficient (E)
was performed to validate specificity of anti-EphA2 and anti-
ephrin-A1 antibodies. Arrows indicate mammary/tumor epithe-
lium in photomicrographs. Scale bar=50 mm. Immunohisto-
Eph/Ephrin Expression Breast Cancer Outcome
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specificity of anti-EphA4 (B), anti-EphA7 (C), anti-EphA8 (D),
anti-EphB4 (F), and anti-EphB6 antibodies. We compared staining
in the presence or absence of competitor peptides that were pre-
incubated with primary antibodies. Arrowheads indicate distal
tubules.
(TIF)
Table S1 Association between Eph receptor expression and
metastasis-free survival in human breast cancer.
(DOCX)
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